LucyRx and Personify Health Join Forces to Tackle Rising Employer GLP-1 Costs with Proven, Member-Centered Solutions
Together, the two companies are helping employers navigate the rising demand and cost of GLP-1 medications with a model that prioritizes member success and long-term cost management for employers.
Share
Through the partnership, LucyRx and Personify Health will deliver an integrated solution that combines pharmacy benefit strategy with personalized support from GLP-1-trained coaches, individualized care plans for medication management, and education from Personify's Transform Weight Management solution. This holistic program provides members with tailored, coach-led guidance, encouragement and resources to effectively manage their weight and medication.
Together, the two companies are helping employers navigate the rising demand and cost of GLP-1 medications with a model that prioritizes member success and long-term cost management for employers. The partnership is especially impactful for health systems and mission-driven employers, where clinical quality and financial accountability go hand in hand.
The new LucyRx/Personify Health joint effort builds on the success employers are already experiencing using LucyRx for GLP-1 management. For example, an 11,000 life employer group has recorded:
An average weight loss per member of 22 pounds in 12 weeks.
40% improvement in medication adherence.
$3.2 million in total health care savings.
90% member-reported satisfaction and improved well-being.
'Employers have an incredible opportunity to reduce long-term health care costs through successful weight management programs like ours,' said David Blair, CEO of LucyRx. 'Partnering with Personify Health allows us to deliver precisely what employers and their members need to be successful and ultimately healthier, which is our primary goal. This collaboration reflects our belief that smarter pharmacy benefits should always prioritize the people we serve.'
Key elements of the joint GLP-1 strategy include:
Targeted prior authorization standards designed to ensure therapy reaches those who will benefit most.
Real-time clinical reviews and benefit optimization powered by LucyIQ™, LucyRx's proprietary AI platform.
Personalized support from certified health coaches from Personify Health.
Menopause-specific care pathways and behavioral health support from LucyRx.
Structured step-down protocols to optimize long-term outcomes.
'Roughly 9% of the U.S. population is predicted to become GLP-1 users by 2030 – that's 30 million people. The growing need for chronic condition support and increasing expectations for employer-sponsored GLP-1 benefits offerings have driven employers to rethink their approach,' said Jeffrey Jacques, MD, chief medical officer at Personify Health. 'Together with LucyRx, we are providing members with meaningful wrap-around support that gives them the tools and education they need for long-lasting, healthy lifestyles – whether using a weight management medication or not.'
About LucyRx
LucyRx is an independent, next-generation pharmacy benefit manager (PBM) redefining prescription care. Fueled by innovation and decades of leadership experience, LucyRx delivers better outcomes through its integrated specialty network, formulary marketplace, and next-day home delivery solutions. Powered by its proprietary AI platform, LucyIQ™, the company provides real-time insights that support evidence-based clinical decisions, clear pricing, and exceptional service from U.S.-based pharmacy technicians. Partnering with more than 60,000 pharmacies, LucyRx serves over 1,200 clients nationwide.
This is prescription care, brilliantly reimagined.
Learn more at LucyRx.com.
About Personify Health
Personify Health empowers diverse and unique businesses – and diverse and unique people – to engage more deeply in health at a lower cost. By bringing modern third party administration, holistic wellbeing, and navigation solutions together, all in one place, we have created the industry's first and only personalized health platform. With global operations and decades of experience (formerly Virgin Pulse and HealthComp), the company engages and empowers people to live healthier lives. Through our proprietary combination of data-driven personalization, science-backed methodology, and concierge-level clinical expertise, our end-to-end platform makes it easier to proactively address people's chronic care to everyday needs. With a personalized, engaging, and powerfully simple experience, we are redefining industry expectations and what it means to manage health. Learn more at www.personifyhealth.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
15 hours ago
- Epoch Times
Taiwanese Doctor Expresses Concern Over China's Organ Industry
A Taiwanese doctor who is part of a medical ethics nonprofit has expressed concerns about China's organ industry, especially regarding children. Huang Shiwei, vice chairman of the medical ethics nonprofit Taiwan International Organ Transplant Care Association, told NTD's Health 1+1 program that he was troubled by an alleged order that a hospital gave medical student Luo Shuaiyu. The medical student, Luo Shuaiyu, specialized in kidney transplantation at the Second Xiangya Hospital of Central South University. Authorities said Luo fell to his death from a building in May 2024, just weeks before his graduation. According to audio recordings released by his parents after his death, Luo had been asked to locate 12 child donors aged 3 to 9, ostensibly for medical purposes. Huang said this is concerning given China's record of forced organ harvesting. 'They asked [Luo] to find child donors. Where was he supposed to look?' Huang said. Pediatric Organs On May 21, 2024, Fudan University Medical College in Shanghai established a pediatric organ transplant center. According to the university, Li Qian, the Chinese Communist Party (CCP) secretary at the pediatric hospital, said that 'in just over a year, [pediatric organ transplants] have exceeded 100 cases.' State media outlet Sina reported that the hospital has performed highly complex surgeries, including kidney transplants from donors weighing less than 5 kg (11 pounds), indicating that newborns are among the donors. In 2017, the First Affiliated Hospital of Sun Yat-sen University in Guangzhou reported that 90 percent of pediatric kidney donors were allocated to adult patients. A 2023 study by doctors from Shanghai Jiao Tong University's Renji Hospital, published in the American Journal of Transplantation, detailed two cases of kidney transplants from newborns born at 29 weeks and 29 weeks, 5 days to adult women aged 34 and 25 with end-stage kidney disease. The kidneys were harvested on the second and third days after birth, prompting ethical scrutiny. Shabih Manzar, associate professor of clinical pediatrics at Louisiana State University, questioned the procedure in the same journal, noting that one of the 29-week preterm infants had no apparent life-threatening conditions, casting doubt on the decision to withdraw life-sustaining treatment. Huang noted the high survival rates of 29-week preterm infants with modern medical technology. 'Whether it's the parents or the medical system, everyone would typically do everything possible to save these preterm newborns,' he said. 'No one would give up and simply designate them as organ donors. Yet, we see that they are using 29-week preterm infants as organ donors.' China's Organ Harvesting Industry China began using organs from executed prisoners following a 1984 regulation allowing the practice. After 1999, when the regime began persecuting the spiritual group Falun Gong, China's organ transplant industry exponentially increased. Huang noted that when former CCP leader Jiang Zemin initiated the persecution campaign against Falun Gong, practitioners were branded as 'class enemies,' making them prime targets for forced organ harvesting. This period marked an unprecedented surge in organ transplants. According to data from the World Organization to Investigate the Persecution of Falun Gong, compiled from Chinese state media reports, only 135 liver transplants were recorded in China over more than two decades before 1999, averaging five to six cases annually. From 1999 to 2006, liver transplants skyrocketed to 14,085 cases over the eight-year period, averaging more than 1,700 cases per year—a 180-fold increase. 'Organ transplantation in China suddenly became a massive industry,' Huang said. 'With countless patients in China and worldwide needing organs, there are enormous commercial interests at play.' In March 2006, a whistleblower using the pseudonym Annie, a former employee of Sujiatun Thrombosis Hospital in Shenyang, Liaoning Province, revealed to The Epoch Times the CCP's horrific practice of forced organ harvesting from Falun Gong practitioners. This exposure had a significant impact on China's organ transplant industry. According to the China Liver Transplant Registry, cited by state media People's Daily, liver transplants peaked at 2,970 cases in 2005 and 2,781 in 2006 but fell by roughly one-third to 1,822 cases in 2007. Huang attributed this decline to the 2006 revelations. 'The reason for the decrease in organ transplants in China in 2007 was the exposure of the CCP's forced organ harvesting from Falun Gong practitioners,' Huang said. 'As relatives relentlessly searched for family members detained for practicing Falun Gong, it became increasingly difficult for the CCP's public security and medical personnel to continue using Falun Gong practitioners' organs on such a large scale.' He said the drop in transplant numbers underscores the international scrutiny and domestic pressure that began to disrupt the CCP's organ harvesting operations. Concerns 'Forced organ harvesting in China appears to be targeting specific ethnic, linguistic, or religious minorities held in detention, often without being explained the reasons for arrest or given arrest warrants, at different locations,' according to a 2021 joint statement from the U.N. Office of the High Commissioner for Human Rights. Huang said: 'In most countries, organ donors tend to be older, 50, 60, or even 70 years old. But in China, the organ transplant industry operates differently. When organs are supplied to wealthy individuals, they naturally demand those from younger people.' Huang said he believes in China there is now an increasing focus on obtaining organs from young individuals, including children. A surge in mysterious disappearances of adolescents across multiple Chinese provinces in recent years has fueled public suspicion of organ trafficking, especially because of China's extensive surveillance infrastructure. In October 2022, Hu Xinyu, a first-year high school student in eastern China's Jiangxi Province, mysteriously disappeared from school. Various reports from insiders and overseas whistleblowers allege that the Hu case is linked to forced organ harvesting. In August 2023, 8-year-old Wang Sijun, who had a rare Rh-negative blood type, died unexpectedly while receiving treatment at Yunnan Red Cross Hospital. According to viral videos posted by her family on platforms such as Douyin, Wang was admitted for a routine examination while accompanying a relative, only to die in the nephrology ward. Her autopsy cited hemorrhagic shock as the cause of death, with traces of the anticoagulant enoxaparin sodium detected, leading her family to suspect blood extraction and organ theft. Although no definitive evidence confirms organ harvesting in the case, Huang noted that widespread allegations of hospitals engaging in such practices have created a climate of heightened anxiety. Documented cases, such as a fraudulent organ donation scandal in Anhui Province's Bengbu City, lend credence to these concerns. Between 2017 and 2018, six defendants, including four doctors, were convicted of deceiving families and illegally harvesting organs from at least 11 patients. 'China's organ transplant industry, driven by the Communist Party's ideology, has evolved into a vast commercial enterprise,' Huang said. 'These cases show it has become an unregulated beast, with rampant, unchecked organ harvesting.'
Yahoo
19 hours ago
- Yahoo
UnitedHealth Group Announces Changes to Leadership Team
July 31, 2025--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) today announced Wayne S. DeVeydt has been appointed its chief financial officer, effective September 2, 2025. John F. Rex, who joined the company in 2012 and has been CFO since 2016, will become strategic advisor to the CEO on the same date. "Wayne DeVeydt combines deep financial acumen and operating experience with the mission-oriented and compassionate approach to health care that is a perfect fit for UnitedHealth Group," said Stephen J. Hemsley, company chairman and chief executive officer. "John Rex has been an exceptional leader, having helped guide our company through substantial change with both strategic vision and strong commitment to our mission," said Hemsley. "I look forward to his continued insights as UnitedHealth Group moves forward." DeVeydt, 55, most recently has been a managing director and operating partner at Bain Capital, working with client leaders on operational improvement and growth acceleration. From 2018-2020, he was chairman and CEO of Surgery Partners, Inc. in Nashville, expanding the operational scale and financial performance of the surgical services firm. He joined Anthem, Inc. (now Elevance) in 2005 and served as its chief financial officer from 2007 to 2016. Prior to joining Anthem, DeVeydt served as a partner with PricewaterhouseCoopers LLP, with a focus on the health care sector. "There is no organization besides UnitedHealth Group that presents the kinds of opportunities to make a difference in health care, from individual patient care to broad system efficiency, so I am eagerly looking forward to joining the team," said DeVeydt. "I've been fortunate to know John Rex for over two decades and am honored to follow a leader of his caliber." Rex, 63, joined UnitedHealth Group as chief financial officer of the company's then newly established Optum business and previously had spent his career focused in health care across multiple roles and sectors. "This pivotal moment for UnitedHealth Group is the right time for a new yet greatly experienced executive like Wayne DeVeydt, and I look forward to supporting him and the entire leadership team while continuing to advise on a range of matters," said Rex. About UnitedHealth Group UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at and follow UnitedHealth Group on LinkedIn. View source version on Contacts Media: uhgmedia@ UnitedHealth Group Media Sign in to access your portfolio
The Hill
20 hours ago
- The Hill
Americans' becoming more aware of GLP-1 drugs like Ozempic, Wegovy: Survey
The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped significantly in the last few years, a new survey shows. The YouGov poll, released Friday, shows that at least 80 percent of respondents have heard at least 'a little bit' about semaglutide, a medication used to treat Type 2 diabetes that also helps a user to shed weight. In March 2023, only 60 percent of Americans were aware of the drug. A year later, in March 2024, that number had jumped to 70 percent, the pollster noted. The latest survey also shows that the share of those who have heard 'a lot' about the medication has nearly doubled since 2023, increasing to 41 percent from 23 percent. Just 36 percent of respondents say they know someone who has taken semaglutide. Around 14 percent listed a family member took the medicine, 16 percent named a friend, 11 percent identified an acquaintance and 7 percent said they had taken it themselves, according to the poll. Several also noted they knew a user in more than one category. Women are more likely than men, 43 percent to 29 percent, to know someone — including themselves — who has taken a GLP-1 agonist drug, per the survey. The weight loss medications — including Wegovy, Ozempic, Zepbound and others — have been available since 2005 but have only in the past few years been used to treat obesity. The drugs work by mimicking a hormone in the body — glucagon-like peptide-1 — that stimulates insulin secretion and reduces appetite. Possible side effects of taking the medication include nausea, diarrhea, vomiting, and constipation. While semaglutide is currently only prescribed for weight loss or treating diabetes, early research is pointing to possible benefits for a host of other issues, including treatment for addiction, neurodegenerative diseases and conditions that affect the heart, kidney or liver. The latest survey found that roughly a quarter of respondents said they would be 'very' or 'somewhat' interested in taking the medication as a weight loss treatment. About a third of Americans have either taken the drug or said they would be interested in trying it. On the other side, about 17 percent said they were 'not very' interested in the medication and 45 percent signaled they were not at all interested. A separate poll from last September found that around a quarter of adults in the U.S. would consider using weight loss medications without consulting their doctor. The YouGov analysis is based on an online survey conducted from May 22-25 among 1,109 adults in the U.S. The margin of error for the full sample is 4 percentage points.
